Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Raltegravir dosage adjustment in HIV-infected patients receiving etravirine.

Do VT, Higginson RT, Fulco PP.

Am J Health Syst Pharm. 2011 Nov 1;68(21):2049-54. doi: 10.2146/ajhp110083.

PMID:
22011983
2.

Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

Taiwo B, Murphy RL, Katlama C.

Drugs. 2010 Sep 10;70(13):1629-42. doi: 10.2165/11538020-000000000-00000. Review.

PMID:
20731472
3.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
4.

Raltegravir: the first HIV integrase inhibitor.

Cocohoba J, Dong BJ.

Clin Ther. 2008 Oct;30(10):1747-65. doi: 10.1016/j.clinthera.2008.10.012. Review.

PMID:
19014832
5.

[Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].

Arazo Garcés P, Omiste Sanvicente T.

Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 10:23-31. Review. Spanish.

PMID:
19195456
6.

Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.

Schiller DS, Youssef-Bessler M.

Clin Ther. 2009 Apr;31(4):692-704. doi: 10.1016/j.clinthera.2009.04.020. Review.

PMID:
19446143
7.

[Role of the new molecules in antiretroviral therapy. Position of raltegravir].

Arribas JR.

Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:53-9. Review. Spanish.

PMID:
19572427
9.

The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients.

Hill AM, Cho M, Mrus JM.

AIDS Rev. 2011 Jan-Mar;13(1):41-8. Review.

PMID:
21412388
10.

[Pharmacokinetics and interactions of raltegravir].

Placeres Alsina MM, Tuset Creus M, Miró JM.

Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:23-8. Review. Spanish.

PMID:
19572422
11.

Etravirine: A novel nonnucleoside reverse transcriptase inhibitor for managing human immunodeficiency virus infection.

Elsayed RK, Caldwell DJ.

Am J Health Syst Pharm. 2010 Feb 1;67(3):193-205. doi: 10.2146/ajhp080559. Review.

PMID:
20101061
12.

Role of raltegravir in HIV-1 management.

Rokas KE, Bookstaver PB, Shamroe CL, Sutton SS, Millisor VE, Bryant JE, Weissman SB.

Ann Pharmacother. 2012 Apr;46(4):578-89. doi: 10.1345/aph.1Q616. Epub 2012 Apr 10. Review.

PMID:
22496475
13.

Etravirine in the treatment of HIV-1: a clinical overview for healthcare professionals.

Yeni P, Mills A, Peeters M, Vingerhoets J, Kakuda TN, De Smedt G, Woodfall B.

Curr HIV Res. 2010 Oct;8(7):564-76. Review.

PMID:
20946097
14.

Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.

Nguyen BY, Isaacs RD, Teppler H, Leavitt RY, Sklar P, Iwamoto M, Wenning LA, Miller MD, Chen J, Kemp R, Xu W, Fromtling RA, Vacca JP, Young SD, Rowley M, Lower MW, Gottesdiener KM, Hazuda DJ.

Ann N Y Acad Sci. 2011 Mar;1222:83-9. doi: 10.1111/j.1749-6632.2011.05972.x. Review.

PMID:
21434946
15.

Raltegravir, an HIV-1 integrase inhibitor for HIV infection.

Cabrera C.

Curr Opin Investig Drugs. 2008 Aug;9(8):885-98. Review.

PMID:
18666037
16.
17.

Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.

Johnson LB, Saravolatz LD.

Clin Infect Dis. 2009 Apr 15;48(8):1123-8. doi: 10.1086/597469. Review.

PMID:
19275497
18.

[Etravirine in highly treatment-experienced patients].

Palter DP, Corbera EF, Tiraboschi JM.

Enferm Infecc Microbiol Clin. 2009 Dec;27 Suppl 2:6-11. doi: 10.1016/S0213-005X(09)73213-6. Review. Spanish.

PMID:
20116622
19.

Raltegravir: the first HIV type 1 integrase inhibitor.

Hicks C, Gulick RM.

Clin Infect Dis. 2009 Apr 1;48(7):931-9. doi: 10.1086/597290. Review.

PMID:
19231980
20.

Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.

Boyd MA, Hill AM.

Pharmacoeconomics. 2010;28 Suppl 1:17-34. doi: 10.2165/11587420-000000000-00000. Review.

PMID:
21182341

Supplemental Content

Support Center